Search Results 261-270 of 18486 for Relapse
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R ...
Clinical Trials · XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia · More about research at Mayo Clinic · Mayo ...
Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Overview · Participation eligibility.
Enzyme inhibitors, such as ibrutinib and ixazomib citrate, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory ...
Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory ...
... (relapsed) or that has not responded to previous treatment (refractory). Participation eligibility. Participant eligibility includes age, gender, type and ...
Cognitive behavioral therapy. Relapse-prevention techniques. 12-step facilitation. Medical options used to promote and maintain recovery. Spiritual support and ...
Participation eligibility · Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin ...
Cancer related outcome events include disease progression or relapse, need for re-treatment or death. Journalists: Sound bites with lead author Matthew ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.